Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Segment Reporting [Line Items] | ||||||||
| Collaboration revenue | $ 0 | $ 0 | $ 0 | $ 7,500 | ||||
| Direct external research and development costs | 99,224 | 74,985 | 187,732 | 136,185 | ||||
| Personnel-related expenses | 27,731 | 22,386 | 56,741 | 45,026 | ||||
| Stock-based compensation expense | 16,732 | 13,713 | 33,626 | 25,887 | ||||
| Other research and development costs | 4,642 | 2,600 | 8,843 | 6,025 | ||||
| Other general and administrative costs | 8,025 | 6,014 | 15,826 | 11,545 | ||||
| Interest income | (12,145) | (7,199) | (19,052) | (15,282) | ||||
| Other segment items | [1] | (274) | (2,324) | (3,393) | (1,932) | |||
| Net loss | (110,736) | $ (102,302) | (84,706) | $ (65,047) | (213,038) | (149,753) | ||
| Azetukalner | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Direct external research and development costs | 55,760 | 43,405 | 102,833 | 74,906 | ||||
| Pain programs | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Direct external research and development costs | 5,582 | 925 | 9,973 | 1,977 | ||||
| Pre-clinical, discovery and other programs | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Direct external research and development costs | $ 4,683 | $ 5,186 | $ 7,641 | $ 9,101 | ||||
| ||||||||
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Personnel related expenses. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|